Results
1 -
10 of
14Emerging Antivirals in the Future, Hepatitis C Virus Treatment A Review of Daclatasvir Drugu2013Drug Interactions, Advances in Therapy Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection, Journal of Gastroenterology Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection, Journal of Gastroenterology Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C, Journal of Gastroenterology Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV, Archives of Virology Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, Journal of Gastroenterology Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection, Hepatology International High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms, Advances in Therapy In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir, Infectious Diseases and Therapy